TNFRSF8 and classic Hodgkin lymphoma: The safety and efficacy of frontline BV in combination with chemotherapy for adults with newly diagnosed stage III/IV cHL or previously untreated CD30-expressing PTCLs was established in the ECHELON-1 and ECHELON-2 trials.